From Print to Screen: Regulatory Considerations to Adopting Innovative Approaches for Patient Information and Safety

11Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Patient information leaflets (PILs) differ across regulatory jurisdictions—its form and structure are dependent on the regulations it conforms to. Yet, physical or paper-based documents remain to be the most prevalent way of delivering important information to patients. As technology continues to enhance our daily activities, patients are increasingly utilizing digital platforms to facilitate access to relevant product information, hence questioning the continuous viability of physical PILs. This paper aims to present the growing importance of transitioning from print to screen via dynamic electronic product information, as a way of expanding access and utility of patient information. It provides considerations or reflection points for regulators when adopting digital platforms to ensure that stakeholders, especially patients, receive trusted and real-time information on available and approved medicinal products. We underscore these with examples and case studies from countries and businesses that have adopted or are transitioning to such platforms.

Cite

CITATION STYLE

APA

Bolislis, W. R. R., Mortazavi, C., Riccioni, R., Schaeffer, P. E., & Kühler, T. C. (2020, July 1). From Print to Screen: Regulatory Considerations to Adopting Innovative Approaches for Patient Information and Safety. Therapeutic Innovation and Regulatory Science. Springer. https://doi.org/10.1007/s43441-019-00018-0

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free